share_log

復宏漢霖:自願公告 - 注射用HLX42(靶向EGFR抗體-新型DNA拓撲異構酶I抑制劑偶聯藥物)獲美國食品藥品管理局(FDA)授予快速通道資格

HENLIUS: VOLUNTARY ANNOUNCEMENT - HLX42 FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETING EGFR WITH NOVEL DNA TOPOISOMERASE I INHIBITOR) HAS BEEN GRANTED THE FAST TRACK DESIGNATION BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA)

香港交易所 ·  Dec 27, 2023 04:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more